Theraclion SA

Theraclion SA is a French medical device company specializing in high-intensity focused ultrasound (HIFU) technology for non-invasive echotherapy treatments. Founded in 2004 and headquartered in Malakoff near Paris, it develops robotic platforms that eliminate the need for surgery, incisions, or scars, enabling treatments in standard physicians' offices. Its flagship products include SONOVEIN, a robotic system for treating varicose veins associated with chronic venous insufficiency, which has CE Mark approval in Europe since 2019 and has treated over 2,500 patients across 15 centers worldwide; and ECHOPULSE, approved for thyroid nodules and breast fibroadenomas. Theraclion SA integrates advanced imaging, AI for decision support, and real-time ultrasound monitoring, protected by 149 patents, to precisely target and destroy diseased tissues point-by-point. The company focuses on vascular, endocrine, and oncology applications, including ongoing trials for breast cancer in collaboration with the University of Virginia, while pursuing US FDA approval via pivotal studies and expansion into China through partnerships. Listed on Euronext Growth Paris since 2014, Theraclion SA plays a key role in advancing minimally invasive medical technologies, optimizing healthcare delivery by reducing costs, recovery times, and procedural complexity.